What are the limitations of the imdc heng criteria?

While the imdc heng criteria is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the imdc heng criteria to ensure safe bedside use and optimal diagnostic accuracy.

How does the imdc heng criteria compare to other Oncology scores?

The imdc heng criteria is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the imdc heng criteria free to use?

Yes. OpiCalc provides the imdc heng criteria completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

IMDC (Heng) Criteria

Genitourinary Cancers

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

KPS < 80%

Diagnosis to treatment < 1 year

Hemoglobin below LLN

Corrected calcium above ULN

Neutrophils above ULN

Platelets above ULN

Calculated Interpretation

Favorable Risk

0 /6

No IMDC adverse factors.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

CLINICAL INSIGHT

How it Works

Clinical Inputs

KPS < 80%

Diagnosis to treatment < 1 year

Hemoglobin below LLN

Corrected calcium above ULN

Neutrophils above ULN

Platelets above ULN

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

OpiCalc Medical Oncology ModuleGenitourinary Cancers2026

CLINICAL INSIGHT

Background

Context

IMDC (Heng) Criteria is included in the oncology module as a structured decision-support tool for genitourinary cancers workflows.

No clinical reference data available.

IMDC (Heng) Criteria

Genitourinary Cancers

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

KPS < 80%

Diagnosis to treatment < 1 year

Hemoglobin below LLN

Corrected calcium above ULN

Neutrophils above ULN

Platelets above ULN

Calculated Interpretation

Favorable Risk

0 /6

No IMDC adverse factors.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

CLINICAL INSIGHT

How it Works

Clinical Inputs

KPS < 80%

Diagnosis to treatment < 1 year

Hemoglobin below LLN

Corrected calcium above ULN

Neutrophils above ULN

Platelets above ULN

CLINICAL INSIGHT

Practical Pearls

Result Bands

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Metastatic RCC risk score for VEGF/IO systemic therapy framing.

OpiCalc Medical Oncology ModuleGenitourinary Cancers2026

CLINICAL INSIGHT

Background

Context

IMDC (Heng) Criteria is included in the oncology module as a structured decision-support tool for genitourinary cancers workflows.

No clinical reference data available.